Bpifrance

Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.

Provepharm life Solutions is a truly unique life sciences research and pharma company, dedicated to a new era of discovery. We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. As PROVEPHARM LIFE SOLUTIONS, we are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

CVasThera is a biopharmaceutical company specializing in the development of novel therapies for cardiovascular and bowel pathologies. It holds an exclusive global license for two patents resulting from four years of joint research between INSERM (French National Institute of Health and Medical Research), the École des Mines d’Albi (a French engineering school) and the GALA platform.

ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Synapse Medicine offers healthcare professionals such as doctors and pharmacists an easy way to look up reliable, up-to-date information about medications, to analyze prescriptions in real-time, and to ensure the safety of drug therapies.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.

In 2011, Alkion BioPharma has been created to revolutionize the secondary metabolims production for cancer therapies. Imperial Innovations, a team of Imperial College researchers and business professionals joined together to develop the technologies able to transform the non-GMO plants into a natural biorefinery. Quickly the technological platform received strong interests from the cosmetic community and the company signed research contracts to develop new disruptive cosmetic ingredients. Four years after inception, with a strong commercial pipeline, Alkion BioPharma has been acquired by Evonik Industries AG for cosmetic & food supplements applications. The new company Alkion BioInnovations was created in March 2017 in order to develop disruptive nutrition, non-cosmetic oil, and agrochemical solutions. The company owns exclusive rights on this applications.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

In 2011, Alkion BioPharma has been created to revolutionize the secondary metabolims production for cancer therapies. Imperial Innovations, a team of Imperial College researchers and business professionals joined together to develop the technologies able to transform the non-GMO plants into a natural biorefinery. Quickly the technological platform received strong interests from the cosmetic community and the company signed research contracts to develop new disruptive cosmetic ingredients. Four years after inception, with a strong commercial pipeline, Alkion BioPharma has been acquired by Evonik Industries AG for cosmetic & food supplements applications. The new company Alkion BioInnovations was created in March 2017 in order to develop disruptive nutrition, non-cosmetic oil, and agrochemical solutions. The company owns exclusive rights on this applications.

Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.